Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Study of VK2735 for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition

NCT06068946 is registered in ClinicalTrials.gov with Viking Therapeutics, Inc. as lead sponsor.

NCT NCT06068946
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06068946 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Study of VK2735 for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition
Lead sponsor
Viking Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2023
Completion date
April 2, 2024
Enrollment
176 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

weight loss